|
Prediction of trifluridine/tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer (mCRC): Real-life data from the Czech Republic. |
|
|
Travel, Accommodations, Expenses - Bayer; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; Pfizer; Roche |
Research Funding - MSD; Roche |
Travel, Accommodations, Expenses - Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Merck Serono; Roche; SERVIER |
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; SERVIER |
|
|
Travel, Accommodations, Expenses - Novartis; Roche; SERVIER |